Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12636131 | 1.00 | CSNK2A1 (0.64) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E | |
| SCHEMBL11327270 | 0.88 | CSNK2A1 (0.64) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E | |
| SCHEMBL20058170 | 0.86 | CSNK2A1 (0.62) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E | |
| SCHEMBL1101378 | 0.86 | HDAC7 (0.57) | CSNK2A1KDM4EMPOGAASMN1; SMN2 | |
| SCHEMBL1637434 | 0.84 | CSNK2A1 (0.60) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E | |
| SCHEMBL13753913 | 0.81 | CSNK2A1 (0.56) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E | |
| SCHEMBL21021862 | 0.81 | PLAU (0.73) | CSNK2A1P2RX1TMPRSS4GRM5SMN1; SMN2 | |
| SCHEMBL14363390 | 0.81 | KCNMA1 (0.66) | CSNK2A1P2RX1TMPRSS4GRM5GAA | |
| SCHEMBL9312494 | 0.81 | EGFR (0.61) | P2RX1KDM4EMPOGAASMN1; SMN2 | |
| SCHEMBL11500852 | 0.80 | CSNK2A1 (0.72) | CSNK2A1P2RX1TMPRSS4GRM5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920018-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416115-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCINECES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8574465-B2 | Organic polymeric photon up-conversion nanoparticles for biological applications | SONY CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8574465-B2 | Organic polymeric photon up-conversion nanoparticles for biological applications | SONY CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130236555-A1 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS | SONY CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20130236555-A1 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS | SONY CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| US-8431051-B2 | Organic polymeric photon up-conversion nanoparticles for biological applications | SONY CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20100301285-A1 | POLYMERIC NANOPARTICLES COMPRISING A MEDIUM FOR PHOTON UP-CONVERSION | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100301285-A1 | POLYMERIC NANOPARTICLES COMPRISING A MEDIUM FOR PHOTON UP-CONVERSION | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1711478-A2 | BENZO [D]ISOXAZOL-3-OL DAAO INHIBITORS | Sepracor Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-4024139-A | ANTIINFLAMMATORY | CARTER-WALLACE, INC. (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CSNK2A1 2695/4885P2RX1 147/4885TMPRSS4 3449/4885 |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | DDO, DAO, CACNA1S | CSNK2A1 352/4885P2RX1 515/4885TMPRSS4 1402/4885 |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CSNK2A1 2695/4885P2RX1 147/4885TMPRSS4 3449/4885 |
| US-20130236555-A1 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS | UPP1, MKI67, PPOX | CSNK2A1 3802/4885P2RX1 1576/4885TMPRSS4 2526/4885 |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | CSNK2A1 2695/4885P2RX1 147/4885TMPRSS4 3449/4885 |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | CSNK2A1 1166/4885P2RX1 4160/4885TMPRSS4 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.